Company news
Bicara Therapeutics Inc. news in 2026
Bicara Therapeutics Inc.'s news releases, calls and decks from 2026, newest first.
Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
November 9, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 4, 2026
Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8: 30 AM ET
November 2, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 5, 2026
Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
August 11, 2026
Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8: 30 AM ET
August 4, 2026
Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors
July 28, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
May 13, 2026
Bicara Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 11, 2026
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8: 30 AM ET
May 4, 2026
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 29, 2026
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8: 30 AM ET
March 22, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
March 4, 2026
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 26, 2026
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
February 24, 2026
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
February 24, 2026
Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen
February 18, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 5, 2026
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
February 4, 2026
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
January 11, 2026
Calls in 2026
- Bicara Therapeutics (NASDAQ:BCAX) Q3 2026 Earnings Call
Nov 9, 2026
Transcript - Bicara Therapeutics (NASDAQ:BCAX) Q2 2026 Earnings Call
Aug 11, 2026
Transcript - Bicara Therapeutics (NASDAQ:BCAX) Q1 2026 Earnings Call
May 11, 2026
Transcript - Bicara Therapeutics (NASDAQ:BCAX) Q4 2025 Earnings Call
Mar 30, 2026
Transcript
Decks in 2026
- Q3 2026 Earnings Presentation
Earnings · 10 slides · Nov 9, 2026
- Q2 2026 Earnings Presentation
Earnings · 8 slides · Aug 11, 2026
- Investor Presentation (August 2026)
Investor deck · 37 slides · August 2026
- Q1 2026 Earnings Presentation
Earnings · 12 slides · May 11, 2026
- Q4 2025 Earnings Presentation
Earnings · 36 slides · Mar 30, 2026
- Technical Presentation (February 2026)
Technical · 18 slides · February 2026